This site is intended for Healthcare professionals only.

Johnson and Johnson scraps Alzheimer’s trials on safety concerns


Johnson and Johnson scraps Alzheimer’s trials on safety concerns

Johnson and Johnson said it would stop mid-stage trials testing its experimental Alzheimer’s drug after observing safety issues, the latest drugmaker to abandon developing treatments for the memory-robbing disease.

Some trial participants showed serious elevations of liver enzymes and the company concluded that the benefit-risk ratio offered by the drug, atabecestat, no longer supported its development, said Janssen, a unit of Johnson and Johnson.

Atabecestat belongs to a class of experimental Alzheimer’s drugs called BACE inhibitors that block an enzyme involved in the production of a protein that creates brain plaques, which are considered a major cause for the disease.

Analysts expect the successful development of a treatment for the disease, which affects about 5.7 million Americans, to virtually guarantee multi-billion dollar annual sales.

However, several drugmakers, including Pfizer Inc, Merck and Co Inc, have been forced to abandon trials over lack of effectiveness or safety concerns.

Eli Lilly & Co and AstraZeneca Plc are testing their BACE inhibitor, lanabecestat, in late-stage trials and are due to report results next year.

Johnson & Johnson was testing atabecestat to slow cognitive decline in certain patients identified to be progressing to Alzheimer’s dementia.

(Reporting by Tamara Mathias in Bengaluru; Additional reporting by Julie Steenhuysen in Chicago; Editing by Sriraj Kalluvila)



Source: REUTERS
0 comment(s) on Johnson and Johnson scraps Alzheimer’s trials on safety concerns

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted